What did @holisticglpgirly actually say?
The video is short and pointed. The creator rattles off three common barriers, "My doctor won't prescribe it," "I can't afford it," "My insurance won't cover it," then repeats "Here you go" three times, implying telehealth or compounding pharmacies solve each problem cleanly. No specific solution is named. The implication is that workarounds exist for all three barriers simultaneously, which is partly true and partly a real oversimplification.
To be fair, the creator isn't making a medical claim here. They're signaling that alternatives exist. That's a legitimate thing to tell people who are genuinely locked out of access. The problem is the framing suggests these workarounds are easy, equivalent, and universally available, and that's where it gets complicated.
Does the science back this up?
The access problem is real and well-documented. This part the creator gets right. A 2023 analysis in JAMA Network Open (Shi et al.) found that out-of-pocket costs for semaglutide exceeded $800 per month for most commercially insured patients without specific coverage riders, and that cost was the leading reason for discontinuation. Separate data from IQVIA through 2023 showed that roughly 50% of GLP-1 prescriptions for weight management were abandoned at the pharmacy counter.
Telehealth platforms have genuinely expanded prescribing access. A 2022 study in Obesity (Almandoz et al.) found that asynchronous telehealth models increased GLP-1 initiation rates in populations previously underserved by endocrinology and primary care. So the "my doctor won't prescribe it" barrier does have a real telehealth-based answer in many cases. The affordability piece is trickier and depends heavily on whether compounded semaglutide or tirzepatide is part of the implied solution.
What did they get wrong (or right)?
They got the problem right. The access barriers they name are documented, systemic, and not the patient's fault. Credit where it's due.
Where it gets shaky is the implied "here you go" resolution. Compounded semaglutide, which is the main affordability lever most of these telehealth-adjacent accounts are gesturing at, is not the same as FDA-approved Wegovy or Ozempic. The FDA has been explicit: compounded drugs are not FDA-approved, and quality can vary significantly between compounding pharmacies. In early 2024, the FDA issued warnings about dosing errors with compounded semaglutide, some involving significantly higher-than-intended doses.
The "my insurance won't cover it" barrier also doesn't have a clean workaround. Manufacturer savings cards like the Novo Nordisk savings program have income and eligibility restrictions. Patient assistance programs have waitlists. Telehealth platforms offering compounded versions at lower prices may help on cost, but they're not closing the insurance gap, they're routing around it, with tradeoffs the video doesn't mention.
What should you actually know?
If you're hitting these barriers, here is what's actually worth knowing. Telehealth can legitimately help with the prescribing access problem. Qualified providers on regulated platforms can evaluate whether GLP-1 therapy is appropriate for you without a six-month wait for a specialist appointment. That's a real benefit.
On cost, compounded semaglutide and tirzepatide are available at lower price points through some telehealth platforms, but they are not interchangeable with brand-name drugs. Ask specifically which pharmacy is compounding, whether it's an FDA-registered 503B outsourcing facility, and what quality testing the pharmacy performs. These are not unfair questions, they're basic ones.
On insurance, the situation is slowly changing. A 2024 KFF analysis found that only 27% of large employer plans covered GLP-1s for obesity as of 2023, but that number is expected to rise as more plans face pressure from outcomes data. If your employer plan doesn't cover it, a formal prior authorization appeal, supported by documented BMI, comorbidities, and a prescriber letter, has a higher success rate than most patients realize. It's not a guaranteed win, but it's not a dead end either.
The bottom line on this video
The creator is pointing people toward real solutions for a real problem. The frustration behind the video is valid. But three "here you go" gestures don't resolve three distinct systemic barriers, and presenting them that way, without any caveats about compounding quality, eligibility limits, or regulatory status, does a disservice to an audience that's already navigating a confusing space. The access crisis around GLP-1 medications deserves honest answers, not just reassurance.